mercredi 20 juin 2012
Dr Stephen Friend
Sage Bionetworks
Originally a pediatric oncologist, Friend ran Merck’s cancer drug efforts until 2010. He says the scientific problems holding back drug discovery are too big for any one company, and he’s combining genetic and other data from multiple companies to help everyone discover more drugs.
Originally a pediatric oncologist, Friend ran Merck’s cancer drug efforts until 2010. He says the scientific problems holding back drug discovery are too big for any one company, and he’s combining genetic and other data from multiple companies to help everyone discover more drugs.
Corey Goodman
Chairman, Oligasis, Second Genome
The biotech vet was hired by Pfizer to try to make the drug giant’s research and development more biotech-like. He left 19 months later. He’s become a convert to the idea of a cheaper, outsourced model focused on breakthroughs, because he thinks only radical change can fix pharma innovation. Photo: Normal 0 false false false EN-US X-NONE X-NONE MicrosoftInternetExplorer4 /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"Times New Roman"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi;} Ryan Anson/Bloomberg/Getty Images
The biotech vet was hired by Pfizer to try to make the drug giant’s research and development more biotech-like. He left 19 months later. He’s become a convert to the idea of a cheaper, outsourced model focused on breakthroughs, because he thinks only radical change can fix pharma innovation. Photo: Normal 0 false false false EN-US X-NONE X-NONE MicrosoftInternetExplorer4 /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"Times New Roman"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi;} Ryan Anson/Bloomberg/Getty Images
William Chin
William Chin
Executive Dean for Research, Harvard Medical School
Chin, who ran drug discovery at Eli Lilly, says “portfolio management” models borrowed from fund managers should be replaced with high-risk, high-reward science. “It’s actually better to spend your money on something more risky and get a breakthrough,” he says.
Executive Dean for Research, Harvard Medical School
Chin, who ran drug discovery at Eli Lilly, says “portfolio management” models borrowed from fund managers should be replaced with high-risk, high-reward science. “It’s actually better to spend your money on something more risky and get a breakthrough,” he says.
Ronald Cohen
Chief Executive, Acorda Therapeutics
A former Off-Broadway actor, Cohen ran Acorda out of his home with a minimum of employees. Last year he brought his first drug to market—Ampyra, for helping multiple sclerosis patients walk. Even after hiring a sales force, Acorda employs only 300 people.
A former Off-Broadway actor, Cohen ran Acorda out of his home with a minimum of employees. Last year he brought his first drug to market—Ampyra, for helping multiple sclerosis patients walk. Even after hiring a sales force, Acorda employs only 300 people.
Francois Nader
Chief Executive, NPS Pharmaceuticals
Nader was a senior vice president at Aventis, one of the biggest drug companies. But when he took over in 2008, he made downsizing the order of the day, cutting head count from 450 to 75. Companies need fewer employees, he says, because many tasks can be handled by consultants.
Nader was a senior vice president at Aventis, one of the biggest drug companies. But when he took over in 2008, he made downsizing the order of the day, cutting head count from 450 to 75. Companies need fewer employees, he says, because many tasks can be handled by consultants.
Tom Hughes
Zafgen has a project too risky for Big Pharma: new obesity drugs that work by making fat cells burn more energy. Despite having raised $66 million in venture capital, Zafgen has only three full-time employees.
